MADD and neoplasm: Concurrently, we noted a significant reduction in tumor weight of MADD siRNA-treated (194 ± 102.2 mg) in contrast to untreated control (445.6 ± 88.17 mg; P < 0.0005) and scramble siRNA-treated tumors (499.6 ± 97.83; P < 0.0005) (Fig. 1f).